Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR001 in adults with classic congenital adrenal hyperplasia
NCT03257462Phase 2Completed
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tildacerfont in congenital adrenal hyperplasia (CAH) (3 cohorts), sponsored by Spruce Biosciences, Inc. Primary endpoints: Safety of SPR001 in Patients With CAH at 6 weeks and 17-hydroxyprogesterone. Started Jul 2017; status: completed.
02
Drugs
tildacerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03257462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257462.